|Last Price$71.45||Day Change (%)-0.28%|
|Open Price$70.87||Day Change ($)-0.20|
|Day Range70.67–71.56||52-Week Range60.84–92.35|
As of Fri 03/14/2014 03:00 PM EST | USD
DuPont Fabros Technology Receives Open- IX Certification For Its ACC5 Data Center
Vestiage Releases Fourth Quarter and Full Year 2013 Results
Etisalat SmartHub IPX and iBasis Peer to Deliver High Quality LTE roaming Experience
Hilltop Holdings Inc. Announces Financial Results for Fourth Quarter and Full Year 2013
Tetragon Financial Group Limited: 2013 Annual Report
CNO Financial Group Announces Sale of Closed Block Life Insurance Subsidiary to Wilton Re
The Carlyle Group Announces Fourth Quarter and Full Year 2013 Financial Results
Mapi Pharma Granted United States Patent Covering the Process for the Preparation of Fingolimod for Multiple Sclerosis
Relevant questions (and answers) for investors as they continue their research into bankruptcy and pension issues.
Regulatory issues that we believe have little impact on Novo Nordisk's long-run prospects have finally helped shares of the leading insulin maker go on sale.